Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Immunotherapeutic Targeting of EphA3

Sara Charmsaz, Kirrilee J Miller, Bryan W Day, PhD, Fares El-Ajeh, PhD, Varghese Palath, PhD, Geoff T Yarranton, PhD, Christopher R Bebbington, DPhil., Andrew M Scott, PhD, Martin Lackmann, PhD, Andrew W Boyd, MD PhD

Blood (2014) 124 (21): 3720.

https://doi.org/10.1182/blood.V124.21.3720.3720

Published: 2014

Journal Articles

Phase I Trial of the Targeted Alpha-Particle Nano-Generator Actinium-225 ( 225 Ac)-Lintuzumab (Anti-CD33; HuM195) in Acute Myeloid Leukemia (AML)

Joseph G. Jurcic, MD, Todd L. Rosenblat, MD, Michael R. McDevitt, PhD, Neeta Pandit-Taskar, MD, Jorge A. Carrasquillo, MD, Suzanne M. Chanel, RN, Kevin Zikaras, BS, Mark G. Frattini, MD, PhD, Peter G. Maslak, M.D., Dragan Cicic, MD, Steven M. Larson, MD, David A. Scheinberg, MD, PhD

Blood (2011) 118 (21): 768.

https://doi.org/10.1182/blood.V118.21.768.768

Published: 2011

Journal Articles

Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model

John M. Pagel, Aimee L. Kenoyer, Tom Bäck, Donald K. Hamlin, D. Scott Wilbur, Darrell R. Fisher, Steven I. Park, Shani Frayo, Amanda Axtman, Nural Orgun, Johnnie Orozco, Jaideep Shenoi, Yukang Lin, Ajay K. Gopal, Damian J. Green, Frederick R. Appelbaum, Oliver W. Press

Blood (2011) 118 (3): 703–711.

https://doi.org/10.1182/blood-2011-04-347039

Published: 2011

Journal Articles

Donor Engraftment Following α-Emitter Astatine-211 ( 211 At) Labeled Anti-CD45 Monoclonal Antibody (mAb) Nonmyeloablative Conditioning for Dog Leukocyte Antigen (DLA)-Identical Marrow Transplantation

Yun Chen, M.D., Brian T Kornblit, M.D., Ph.D., Hirohisa Nakamae, M.D., Ph.D., Donald K Hamlin, Ph.D., Erlinda B Santos, Rainer Storb, MD, D. Scott Wilbur, Brenda M. Sandmaier, MD

Blood (2010) 116 (21): 76.

https://doi.org/10.1182/blood.V116.21.76.76

Published: 2010

Journal Articles

Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease

Steven I. Park, Jaideep Shenoi, John M. Pagel, Don K. Hamlin, D. Scott Wilbur, Nural Orgun, Aimee L. Kenoyer, Shani Frayo, Amanda Axtman, Tom Bäck, Yukang Lin, Darrell R. Fisher, Ajay K. Gopal, Damian J. Green, Oliver W. Press

Blood (2010) 116 (20): 4231–4239.

https://doi.org/10.1182/blood-2010-05-282327

Published: 2010

Journal Articles

Conventional and Pretargeted Radioimmunotherapy with Bismuth-213 to Target and Treat CD20-Expressing Non-Hodgkin Lymphoma: A Preclinical Model for Consolidation Therapy to Eradicate Minimal Residual Disease.

Steven I. Park, MD, Jaideep Shenoi, MD, John M. Pagel, MD, PhD, Donald K. Hamlin, Nural Orgun, Aimee L. Kenoyer, Shani M. Wilbur, BS, Amanda Axtman, D. Scott Wilbur, PhD, Yukang Lin, PhD, Darrell R. Fisher, PhD, Ajay K. Gopal, MD, Damian J. Green, MD, Oliver W. Press, MD, PhD

Blood (2009) 114 (22): 2705.

https://doi.org/10.1182/blood.V114.22.2705.2705

Published: 2009

Journal Articles

Sequential Cytarabine and Alpha-Particle Immunotherapy with Bismuth-213 ( 213 Bi)-Labeled-HuM195 (Lintuzumab) for Acute Myeloid Leukemia (AML)

Todd Rosenblat, MD, MS, Michael R. McDevitt, PhD, Deborah A. Mulford, MD, Neeta Pandit-Taskar, MD, Mark A. Weiss, MD, Mark L. Heaney, MD, PhD, Suzanne Chanel, RN, Alfred Morgenstern, PhD, Steven M. Larson, MD, David A. Scheinberg, MD, PhD, Joseph G. Jurcic, MD

Blood (2008) 112 (11): 2983.

https://doi.org/10.1182/blood.V112.11.2983.2983

Published: 2008

Journal Articles

Evaluation of Toxicity and Tissue Radiation Doses Obtained in Mice with An Anti-CD45 Monoclonal Antibody (mAb) Labeled with the Alpha-Emitting Radionuclides, Astatine-211 or Bismuth-213.

Hirohisa Nakamae, MD, PhD, D. Scott Wilbur, PhD, Donald K Hamlin, Monica S Thakar, MD, Erlinda B Santos, Darrell R Fisher, PhD, Amiee L Kenoyer, John M. Pagel, MD, PhD, Oliver W. Press, MD, PhD, Rainer F. Storb, MD, Brenda M. Sandmaier, MD

Blood (2008) 112 (11): 3270.

https://doi.org/10.1182/blood.V112.11.3270.3270

Published: 2008

Journal Articles

Phase I Trial of the Targeted Alpha-Particle Nano-Generator Actinium-225 ( 225 Ac)-HuM195 (Anti-CD33) in Acute Myeloid Leukemia (AML).

Todd L. Rosenblat, MD, Michael R. McDevitt, PhD, Neeta Pandit-Taskar, MD, Jorge A. Carrasquillo, MD, Suzanne Chanel, RN, Mark G. Frattini, MD, PhD, Steven M. Larson, MD, David A. Scheinberg, MD, PhD, Joseph G. Jurcic, MD

Blood (2007) 110 (11): 910.

https://doi.org/10.1182/blood.V110.11.910.910

Published: 2007

Journal Articles

The Clinical Efficacy of Helicobacter pylori Eradication in Patients with Helicobacter pylori -Positive Chronic Thrombocytopenic Purpura.

Seung-Hyun Nam, MD, Bong-Seog Kim, MD, Jae Hoon Lee, MD, Hong Suk Song, MD, Sung-Hwa Bae, MD, Myung Soo Hyun, MD, Young Jin Yuh, MD, Sang-Jae Lee, MD, Seonyang Park, MD

Blood (2005) 106 (11): 4002.

https://doi.org/10.1182/blood.V106.11.4002.4002

Published: 2005

Journal Articles

Involvement of PKCe in the Negative Regulation of Akt Activation Stimulated by G-CSF.

Hong Liu, M.D., Ph.D., Fan Dong, M.D., Ph.D.

Blood (2004) 104 (11): 2187.

https://doi.org/10.1182/blood.V104.11.2187.2187

Published: 2004

Journal Articles

Sequential Therapy with Cytarabine and Bismuth-213 ( 213 Bi)-Labeled-HuM195 (Anti-CD33) for Acute Myeloid Leukemia (AML).

Deborah A. Mulford, M.D., Neeta Pandit-Taskar, M.D., Michael R. McDevitt, Ph.D., Ronald D. Finn, Ph.D., Mark A. Weiss, M.D., Christos Apostolidis, Ph.D., Alfred Morgenstern, Ph.D., Chaitanya R. Divgi, M.D., Steven M. Larson, Ph.D., David A. Scheinberg, M.D., Ph.D., Joseph G. Jurcic, M.D.

Blood (2004) 104 (11): 1790.

https://doi.org/10.1182/blood.V104.11.1790.1790

Published: 2004

Journal Articles

Additional alpha applications

David A. Scheinberg

Blood (2003) 101 (12): 4651.

https://doi.org/10.1182/blood-2003-04-1079

Published: 2003

Journal Articles

Selective T-cell ablation with bismuth-213–labeled anti-TCRαβ as nonmyeloablative conditioning for allogeneic canine marrow transplantation

Wolfgang A. Bethge, D. Scott Wilbur, Rainer Storb, Donald K. Hamlin, Erlinda B. Santos, Martin W. Brechbiel, Darrell R. Fisher, Brenda M. Sandmaier

Blood (2003) 101 (12): 5068–5075.

https://doi.org/10.1182/blood-2002-12-3867

Published: 2003

Journal Articles

Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the α-emitting radionuclide, bismuth 213

Meili Zhang, Zhengsheng Yao, Kayhan Garmestani, Donald B. Axworthy, Zhuo Zhang, Robert W. Mallett, Louis J. Theodore, Carolyn K. Goldman, Martin W. Brechbiel, Jorge A. Carrasquillo, Thomas A. Waldmann

Blood (2002) 100 (1): 208–216.

https://doi.org/10.1182/blood-2002-01-0107

Published: 2002

Journal Articles

Bismuth 213–labeled anti-CD45 radioimmunoconjugate to condition dogs for nonmyeloablative allogeneic marrow grafts

Brenda M. Sandmaier, Wolfgang A. Bethge, D. Scott Wilbur, Donald K. Hamlin, Erlinda B. Santos, Martin W. Brechbiel, Darrell R. Fisher, Rainer Storb

Blood (2002) 100 (1): 318–326.

https://doi.org/10.1182/blood-2001-12-0322

Published: 2002

NARROW

Immunotherapeutic Targeting of EphA3

Phase I Trial of the Targeted Alpha-Particle Nano-Generator Actinium-225 ( 225 Ac)-Lintuzumab (Anti-CD33; HuM195) in Acute Myeloid Leukemia (AML)

Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model

Donor Engraftment Following α-Emitter Astatine-211 ( 211 At) Labeled Anti-CD45 Monoclonal Antibody (mAb) Nonmyeloablative Conditioning for Dog Leukocyte Antigen (DLA)-Identical Marrow Transplantation

Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease

Conventional and Pretargeted Radioimmunotherapy with Bismuth-213 to Target and Treat CD20-Expressing Non-Hodgkin Lymphoma: A Preclinical Model for Consolidation Therapy to Eradicate Minimal Residual Disease.

Sequential Cytarabine and Alpha-Particle Immunotherapy with Bismuth-213 ( 213 Bi)-Labeled-HuM195 (Lintuzumab) for Acute Myeloid Leukemia (AML)

Evaluation of Toxicity and Tissue Radiation Doses Obtained in Mice with An Anti-CD45 Monoclonal Antibody (mAb) Labeled with the Alpha-Emitting Radionuclides, Astatine-211 or Bismuth-213.

Phase I Trial of the Targeted Alpha-Particle Nano-Generator Actinium-225 ( 225 Ac)-HuM195 (Anti-CD33) in Acute Myeloid Leukemia (AML).

The Clinical Efficacy of Helicobacter pylori Eradication in Patients with Helicobacter pylori -Positive Chronic Thrombocytopenic Purpura.

Involvement of PKCe in the Negative Regulation of Akt Activation Stimulated by G-CSF.

Sequential Therapy with Cytarabine and Bismuth-213 ( 213 Bi)-Labeled-HuM195 (Anti-CD33) for Acute Myeloid Leukemia (AML).

Additional alpha applications

Selective T-cell ablation with bismuth-213–labeled anti-TCRαβ as nonmyeloablative conditioning for allogeneic canine marrow transplantation

Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the α-emitting radionuclide, bismuth 213

Bismuth 213–labeled anti-CD45 radioimmunoconjugate to condition dogs for nonmyeloablative allogeneic marrow grafts

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only